2009年12月通期決算の純利益は84億5,000万ドルで、前年から4％増加。特許薬とワクチン事業が好調だったほか、為替変動も有利に働き、過去最高益を記録した。売上高は7％増の443億ドル。10－12月期は純利益が前年同期比54％増の23億2,000万ドル、売上高が28％増の129億3,000万ドルだった。同社はダニエル・ヴァセラ最高経営責任者（CEO）が今月末で退任。後任には特許薬部門を統括するジョセ・ジメンツ氏が就任する。
\
| Cookie | 期間 | 説明 |
|---|---|---|
| cookielawinfo-checbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |